Literature DB >> 16018941

Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression.

Gustavo A Heresi1, Jingcheng Wang, Russell Taichman, Julio A Chirinos, Jacinto J Regalado, Daniel M Lichtstein, Joseph D Rosenblatt.   

Abstract

PURPOSE: Generalized lymphadenopathy is a rare presentation of prostate cancer. We report a case and review reported cases in the literature. Because of the association of chemokine receptor expression with specific metastatic patterns, we tested for expression of chemokine receptors known to mediate migration to lymph nodes.
METHODS: We performed a MEDLINE (National Library of Medicine, Bethesda, MD) database search for case reports during the last 32 years using "prostate cancer," "lymphadenopathy," "metastatic to lymph nodes," and "mimicking lymphoma" as keywords. Expression of the CXCR4 and CCR7 chemokine receptors was assessed by immunohistochemistry. Laser capture microdissection and reverse transcription polymerase chain reaction for CXCR4 were used to exclude nonspecific binding.
RESULTS: Of 153 patients with prostate cancer presenting with lymphadenopathy (LAD) described in the literature, 67 (44%) presented with supraclavicular adenopathy, 29 (19%) retroperitoneal, 22 (14%) mediastinal, 15 (10%) cervical, 9 (6%) inguinal, and 2 (1%) axillary LAD. Only 9 patients presenting with generalized LAD have been previously reported. Monoclonal antibodies to CCR7 showed intense staining in the patient's tumor epithelium. Little or no staining was observed for CXCR4. Reverse transcription polymerase chain reaction for chemokine receptors on ribonucleic acid (RNA) recovered from the patient's sample failed to express messenger RNA for CXCR4 but did express messenger RNA for CCR1, CCR4, and CCR5.
CONCLUSIONS: Prostate cancer may present on rare occasions with generalized adenopathy. Variable expression of chemokine receptors may be associated with organ specific patterns of metastasis. In this case, expression of CCR7 may have accounted for the unusual predilection of this patient's prostate cancer for lymph nodes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16018941     DOI: 10.1016/j.urolonc.2005.02.004

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  20 in total

1.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

Authors:  Shailesh Singh; Rajesh Singh; Praveen K Sharma; Udai P Singh; Shesh N Rai; Leland W K Chung; Carlton R Cooper; Kristian R Novakovic; William E Grizzle; James W Lillard
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

2.  Primary Non-Hodgkin Lymphoma of Prostate: a Case Report.

Authors:  R B Nerli; Adarsh Sanikop; Manas Sharma; Priyeshkumar Patel; Ranjit Kangale; Shashank Patil; Shridhar C Ghagane; Murigendra B Hiremath; Neeraj S Dixit
Journal:  Indian J Surg Oncol       Date:  2020-08-31

Review 3.  Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.

Authors:  Angus Dalgleish; Peter Featherstone; Viatcheslav Vlassov; Moshe Rogosnitzky
Journal:  Invest New Drugs       Date:  2014-01-18       Impact factor: 3.850

4.  Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.

Authors:  Bao-Jin Chi; Cong-Lin Du; Yun-Feng Fu; Ya-Nan Zhang; Ru Wen Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.

Authors:  Shailesh Singh; Rajesh Singh; Udai P Singh; Shesh N Rai; Kristian R Novakovic; Leland W K Chung; Peter J Didier; William E Grizzle; James W Lillard
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

Review 6.  G-protein coupled chemoattractant receptors and cancer.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Nancy M Dunlop; Ji Ming Wang
Journal:  Front Biosci       Date:  2008-05-01

Review 7.  Chemokines and chemokine receptors as promoters of prostate cancer growth and progression.

Authors:  Nicole Salazar; Miguel Castellan; Samir S Shirodkar; Bal L Lokeshwar
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2013       Impact factor: 1.807

Review 8.  Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.

Authors:  Ganna Chornokur; Nagi B Kumar
Journal:  Cancer Causes Control       Date:  2013-06-05       Impact factor: 2.506

9.  Superior vena cava syndrome as a presentation of metastatic prostate cancer.

Authors:  Hyun Don Yun; William B Ershler
Journal:  BMJ Case Rep       Date:  2012-09-03

10.  Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo.

Authors:  Silvia Lanati; Darryl B Dunn; Myriam Roussigné; Maxine S Emmett; Virginie Carriere; Denis Jullien; Jessica Budge; Justin Fryer; Monique Erard; Françoise Cailler; Jean-Phillippe Girard; David O Bates
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.